title: Suppressive effect of iodine on DMBA-induced breast tumor growth in the rat.
abstract: Concerning the suppressive effect of inorganic iodine on the growth of 7,12-dimethyl-benz(a)anthracene (DMBA)-induced breast tumor in female Sprague-Dawley (SD) rats, we previously reported that although iodine itself had a suppressive effect on the tumor growth, its effect was not as strong as that of MPA (medroxy-progesterone acetate). However, the combined medication of iodine at a low concentration + MPA showed a stronger effect than MPA alone. The purpose of the present study is to elucidate this mechanism of action by determining the uptake of the administered iodine into breast tumor tissue. Breast tumors were induced with DMBA in female SD rats, and these animals were treated with MPA + inorganic iodine at various concentrations for 4 weeks to determine tumor growth and tumor iodine content. In the comparison of tissue iodine content in growth-suppressive tumors with that in nonsuppressive tumors, the former showed a much higher iodine content. This suggests that direct uptake of inorganic iodine by breast tumors led to the suppression of tumor growth.
authors.affiliation: Department of Surgery II, Nagoya University School of Medicine, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Funahashi
authors.forename: T
authors.initials: T
authors.lastname: Imai
authors.forename: Y
authors.initials: Y
authors.lastname: Tanaka
authors.forename: J
authors.initials: J
authors.lastname: Tobinaga
authors.forename: M
authors.initials: M
authors.lastname: Wada
authors.forename: T
authors.initials: T
authors.lastname: Morita
authors.forename: F
authors.initials: F
authors.lastname: Yamada
authors.forename: K
authors.initials: K
authors.lastname: Tsukamura
authors.forename: M
authors.initials: M
authors.lastname: Oiwa
authors.forename: T
authors.initials: T
authors.lastname: Kikumori
authors.forename: T
authors.initials: T
authors.lastname: Narita
authors.forename: H
authors.initials: H
authors.lastname: Takagi
mesh_terms: D015127:9,10-Dimethyl-1,2-benzanthracene / Q000009:adverse effects*; D000818:Animals; D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000493:pharmacokinetics / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D005260:Female; D006131:Growth Inhibitors / Q000493:pharmacokinetics / Q000627:therapeutic use*; D007455:Iodine / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008321:Mammary Glands, Animal / Q000378:metabolism / Q000473:pathology; D008325:Mammary Neoplasms, Experimental / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D017258:Medroxyprogesterone Acetate / Q000493:pharmacokinetics / Q000627:therapeutic use; D051381:Rats; D017207:Rats, Sprague-Dawley; D013961:Thyroid Gland / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D006131:Growth Inhibitors; D015127:9,10-Dimethyl-1,2-benzanthracene; D007455:Iodine; D017258:Medroxyprogesterone Acetate